Health · Pharma & Biotech · 2 hrs ago
Merck’s eye drug meets main study goal, but results are mixed
Merck is developing remigromig, a drug candidate for diabetic macular edema, an eye condition.
The company tested it in a pivotal study, a major clinical trial.
Remigromig met the study’s primary endpoint, or main goal.
But the full results were mixed.
They raise questions about the drug’s prospects as a commercial product.
No further steps for the drug were described.
Merck said its eye drug candidate remigromig met the primary endpoint in a pivotal study.
The study concerned diabetic macular edema.
The reported results were mixed.
The full results raised questions about the drug’s commercial prospects.
- Who
- Merck.
- What
- Its candidate remigromig met the primary endpoint in a pivotal study, but the results were mixed.
- When
- Merck reported the results on October 12, 2026.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug candidate
- Remigromig
- Company
- Merck
- Study
- Pivotal study in diabetic macular edema
- Main result
- Met the primary endpoint
- Results
- Mixed
Sources
Related news
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Italian Registry Study Finds Avacopan Appeared Effective for AAV
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Brazil suspends Peptistrong supplement and orders all batches recalled
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
